Grand View Research, Inc. – Market Research And Consulting.
According to report published by Grand View Research, Increasing prevalence of chronic respiratory disorders augments the demand for intranasal drug and vaccine devices as they are commonly prescribed by medical professionals owing to the easy self-administration technique.
According to a report, “Intranasal Drug And Vaccine Delivery Market Size, Share & Trends Analysis Report By Product (Liquid Delivery Device, Powder Delivery Device), By Dosage, By Application, By Distribution Channel, And Segment Forecasts, 2020 – 2027”, published by Grand View Research, Inc., The global intranasal drug and vaccine delivery market is anticipated to be worth USD 82.0 billion by the year 2027, advancing at a CAGR of 6.5% through the forecast period, according to a recent Grand View Research report. Intranasal route of drug administration has been long-known to medical professionals, and has a great potential for the treatment of a number of disorders. The nasal mucosa, whose surface in humans is around 150 sq.cm, and is well-supplied by blood vessels, can be effectively used for non-invasive systemic drug administration, as this route enables rapid absorption of most drugs. Moreover, the nasal system avoids first pass metabolism that needs to be considered in cases of oral administration. As such, the intranasal drug and vaccine delivery has gained prominence over parenteral and oral routes for instant relief in recent years, driving industry growth.
The rising prevalence of chronic respiratory disorders has contributed to the growth of the industry. CDC reports from 2019 state that 1 out of 13 people in the US have asthma, which translated to around 25 million people. Also, asthma led to an approximate 1.2 million hospital visits, along with 1.8 million emergency department visits per year in the country. Additionally, the International Study of Asthma and Allergies in Childhood (ISAAC) published in World Allergy Organization Journal 2018 stated that globally, the prevalence of allergic rhinitis is between 0.8% to 14.9% in 6-7 years age group and 1.4%-39.7% in 13-14 years. In the US, 2016 saw 11% of the total population (around 26.9 million adults) being diagnosed with sinusitis, while the U.S. National Library of Medicine National Institutes of Health study published in 2018 estimated migraine prevalence rates in the country between 2.6-21.7% All these statistics point towards the importance and increasing proliferation of intranasal drug administration routes in healthcare settings. Additional factors influencing industry growth are the continued technological advancements in this space, along with increased patient satisfaction and compliance.
“Would you Like/Try a Sample Report” Click the link below: https://www.grandviewresearch.com/industry-analysis/intranasal-drug-and-vaccine-delivery-market/request/rs5
In terms of distribution channel, the market is classified into retail pharmacies, online pharmacies and hospital pharmacies. The retail segment held the largest market share in 2019, owing to the rising patient awareness, self-administration, and increasing focus on positive medical outcomes. On the other hand, the online segment is expected to become a lucrative revenue channel in the near future, due to discounts offered, as well as cost-effectiveness to patients and payers in the long run. The major application areas of the industry include respiratory disorders, neurological disorders, vaccination and pain management, among others. Intranasal devices are used in the treatment of a number of respiratory disorders such as asthma, allergic rhinitis and nasal congestion.
Trends and developments:
The ongoing COVID-19 pandemic has seen the medical and research community try to come up with an effective drug. To this extent, researchers are studying upon the effectiveness of intranasal drug administration on the various CNS (Central Nervous System) manifestations in the more severe coronavirus cases. More recently, Azelastine, which is an antihistamine available as a nasal spray, was identified at CEBINA GmbH’s COVID-19 drug repurposing project as a potential topical preventive or post-exposure combatant to COVID-19. Similar approaches in the coming months can be expected to drive the growth of the intranasal drug and vaccine delivery market.
North America has been the industry leader in recent years, both in terms of revenue and technological advances, along with the increasing prevalence of chronic respiratory disorders such as sinusitis and rhinitis in the US. This, combined with the high incidence of COVID-related cases, is expected to offer further impetus to manufacturers for launching effective intranasal drug delivery mechanisms in coming months. Asia Pacific is also expected to show great progress in the market, with the rapid emergence of market players bringing novel products in the market expected to aid in the regional development. Companies such as Bharat Biotech, an India-based vaccine developer, are expected to undertake partnerships in coming months with established research institutes to develop intranasal drugs and vaccines for tackling COVID-19.
Optinose, which is an allergy and ENT specialist pharma company, recently announced the initiation of development of a new product candidate, OPN-019, which combine’s the company’s proprietary nasal Exhalation Delivery System (EDS) technology, with an antiseptic that has shown to kill the virus that causes COVID-19 in-vitro. The company is currently seeking grants and partnerships, among other sources of capital, in order to fund future development.
Have Any Query? Ask Our Experts for More Details on Report: https://www.grandviewresearch.com/inquiry/450533/ibb
Application Insights
Based on the application, the market for intranasal drug and vaccine delivery is segmented into respiratory disorders, neurological disorders, vaccination, pain management, and others. The respiratory disorders segment accounted for the dominant share of 41.2% in 2019. This is mainly attributed to the use of intranasal devices for treating a variety of respiratory disorders, such as asthma, nasal congestion, and allergic rhinitis.
According to the Centers for Disease Control and Prevention, in 2016, an estimated 26.5 million adults and children in the U.S. have asthma and approximately 1.7 million emergency department visits were recorded with asthma in 2015. According to an article in The Journal of Allergy and Clinical Immunology, in 2016, allergic rhinitis affected 10-40% of the total population in the world. Nasal sprays, drops, nebulizers, and irrigations are used for the treatment of allergic rhinitis. Moreover, in March 2020, the American College of Allergy, Asthma & Immunology (ACAAI) provided a guidance document for patients with allergies and asthma to continue the use of intranasal corticosteroids during the COVID-19 pandemic.
Intranasal Drug And Vaccine Delivery Market Segmentation
Grand View Research has segmented the global intranasal drug and vaccine delivery market based on product, dosage, application, distribution channel, and region:
Intranasal Drug and Vaccine Delivery Product Outlook (Revenue, USD Million, 2016 – 2027)
Intranasal Drug and Vaccine Delivery Dosage Outlook (Revenue, USD Million, 2016 – 2027)
Intranasal Drug and Vaccine Delivery Application Outlook (Revenue, USD Million, 2016 – 2027)
-
Respiratory Disorders
-
Neurological Disorders
-
Vaccination
-
Pain management
-
Others
Intranasal Drug and Vaccine Delivery Distribution Channel Outlook (Revenue, USD Million, 2016 – 2027)
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
Intranasal Drug and Vaccine Delivery Regional Outlook (Revenue, USD Million, 2016 – 2027)
-
North America
-
Europe
-
U.K.
-
Germany
-
France
-
Italy
-
Spain
-
Russia
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Malaysia
-
Thailand
-
South Korea
-
-
Latin America
-
Brazil
-
Mexico
-
Argentina
-
Columbia
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Qatar
-
List of Key Players of Intranasal Drug And Vaccine Delivery Market
-
GlaxoSmithKline Plc
-
Teva Pharmaceuticals
-
Aptar Pharma
-
UCB, Inc.
-
Teleflex Corporation
-
3M
-
Bespak
-
OptiNose, Inc.
-
Intersect ENT
Request for Customization : https://www.grandviewresearch.com/request-for-customization/450533/rfc1
Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address: 201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/intranasal-drug-and-vaccine-delivery-market
